A Review on The Use of Dapagliflozin in Cardiovascular Diseases
| Autor: | Satish S, Shifnaz N P, A R Shabaraya |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | International Journal of Research and Review. 10:45-51 |
| ISSN: | 2349-9788 2454-2237 |
| DOI: | 10.52403/ijrr.20230106 |
| Popis: | Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor (SGLT2), used in decreasing the blood sugar levels in Type 2 diabetes mellitus patients by boosting urine glucose excretion, which also reduces the incidence of major adverse cardiovascular events. The drug has a higher affinity for cardio-protection and is observed to have reduced the risk of cardiovascular events in clinical trials and benefited in the prevention of cardiovascular diseases. It is recommended especially in patients with pre-existing CV conditions such as hypertension or myocardial infarction due to its higher baseline risk, but the use of drug was cautioned in patients who take pioglitazone or loop diuretics for hypertensive diabetes as it is believed to cause further volume depletion, resulting in lower eGFR. Dapagliflozin is a crucial treatment choice for a variety of individuals despite of its advised risk and regardless of patient history of cardiovascular disease, as it improves glycaemic control, body weight, and blood pressure while lowering the risk of cardiovascular mortality. This study reviews the therapeutic efficacy and the effects of dapagliflozin in diabetic patients with coexisting cardiovascular conditions and also compares several recent publications to comprise the risk and benefits of the drug in cardiovascular events and its role in the prevention of cardiovascular diseases and their complications. Keywords: Dapagliflozin, sodium-glucose co-transporter 2 inhibitor (SGLT2), cardiovascular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|